http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#Head http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#provenance http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#pubinfo http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion http://purl.obolibrary.org/obo/DOID_3908 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3908 http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB05578 http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association http://www.w3.org/2000/01/rdf-schema#label cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastro esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinum containing chemotherapy 1 1 in combination with docetaxel for treatment of metastatic non small cell lung cancer with disease progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza 1 2 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 1 3 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 4 ng ml and have been treated with sorafenib 1 4 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with disease progression on or after platinum based chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB05578 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#provenance http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#pubinfo http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig http://purl.org/nanopub/x/hasSignature NHdqiLdcFb7j9YujwVJrDrMfkUPvXCqcenz4XiQ0UEXXvgHk67/940GvpvzqdPUU5970D3wh6hrbx9v2xzNIDpVmcj5gWGIA7eMNC8+4XEfHsCHs3N04r8Ir1kM+2NeoaNgy5d2HjIw7YReC6IrEkMGkoxDBwfyq3mu/L/lfhsI= http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://purl.org/dc/terms/created 2021-07-03T14:43:26.175+02:00 http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs